<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01246778</url>
  </required_header>
  <id_info>
    <org_study_id>SCAR</org_study_id>
    <nct_id>NCT01246778</nct_id>
  </id_info>
  <brief_title>Sunitinib and Atrial Trabeculae Contractility</brief_title>
  <acronym>SCAR</acronym>
  <official_title>The Influence of Sunitinib on Contractility of Human Atrial Trabeculae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      Recently, sunitinib (a tyrosine kinase inhibitor that is used for treatment of metastatic
      renal carcinoma and gastrointestinal stroma tumors) has been associated with development of
      heart failure, possibly by off-target inhibition of AMP-protein kinase. The investigators
      hypothesize that sunitinib reduces the contractile ability of myocardium and the tolerance
      against ischemia-reperfusion and that activators of AMP-protein kinase such as atorvastatin
      and AICAR reverse this unwanted effect of sunitinib.

      Objectives:

      The primary objective of the study is to investigate the effect of sunitinib on ex-vivo
      atrial contractile force in absence and presence of ischemia-reperfusion.

      A secondary objective is to explore if atorvastatin or AICAR prevent sunitinib-induced
      deterioration of contractile function of human atrial trabeculas. Study design: Lab
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study population: 44 (+22) patients undergoing CABG cardiac surgery with extracorporal
      circulation Intervention (if applicable): none (pharmacological interventions will only be
      performed ex-vivo in isolated atrial tissue) Main study parameters/endpoints The developed
      force in ex vivo atrial trabeculas during standardized stimulation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Force</measure>
    <time_frame>200 minutes</time_frame>
    <description>The developed force in ex vivo atrial trabeculae during standardized stimulation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Speed</measure>
    <time_frame>200 minutes</time_frame>
    <description>The difference in averaged maximal speed of tension reduction during relaxation between two trabeculae</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal Speed</measure>
    <time_frame>210 minutes</time_frame>
    <description>The difference in averaged maximal speed of tension development during contraction between two trabeculae.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Cardiotoxicity</condition>
  <condition>Ischemia</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>With/without sunitinib</arm_group_label>
    <description>Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction during 200 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>With/without sunitinib IP</arm_group_label>
    <description>Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction and ischemia/reperfusion</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Atrial tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        44 patients undergoing cardiac surgery with extracorporal circulation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cardiac surgery with extracorporal circulation

        Exclusion Criteria:

          -  Use of oral antiarrhythmics

          -  theophylline use

          -  Use of sulfonylureas

          -  Atrial arrythmias

          -  Right ventricular failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>G. A. Rongen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2010</study_first_submitted>
  <study_first_submitted_qc>November 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2010</study_first_posted>
  <last_update_submitted>April 30, 2014</last_update_submitted>
  <last_update_submitted_qc>April 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Radboud University</investigator_affiliation>
    <investigator_full_name>G. Rongen</investigator_full_name>
    <investigator_title>Prof. dr. Rongen</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

